← Back to Search

Local Anesthetic

Exparel for Postoperative Pain

Phase 4
Waitlist Available
Led By Adam Schumaier, MD
Research Sponsored by University of Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
patients who are older than 18 years
patients undergoing reverse total shoulder arthroplasty
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 hours post-operatively
Awards & highlights

Study Summary

This trial is studying two different pain management interventions for people undergoing reverse shoulder surgery. The primary aim is to compare the two interventions on post-operative opioid consumption, pain scores, and patient satisfaction.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~catastrophizing will be measured pre-operatively
This trial's timeline: 3 weeks for screening, Varies for treatment, and catastrophizing will be measured pre-operatively for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Opioid Consumption
Patient Satisfaction: Rating
Relationship between catastrophizing, pain, and patient satisfaction
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Liposomal BupivacaineExperimental Treatment1 Intervention
Patients in this group will receive a single intra-operative injection of liposomal bupivacaine near the surgical site (40 ml total: consisting of 20 ml 1.3% liposomal bupivacaine and 20 ml normal saline).
Group II: Interscalene Nerve BlockExperimental Treatment1 Intervention
Patients in this group will receive a single pre-operative interscalene nerve block in the neck/shoulder consisting of 30 ml 0.5% ropivacaine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exparel
2014
Completed Phase 4
~1620
Interscalene Nerve Block
2016
Completed Phase 4
~280

Find a Location

Who is running the clinical trial?

University of CincinnatiLead Sponsor
427 Previous Clinical Trials
634,295 Total Patients Enrolled
Adam Schumaier, MDPrincipal Investigator - University of Cincinnati, Department of Orthopaedics and Sports Medicine
University of Cincinnati

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Exparel received governmental authorization for use?

"With a Phase 4 trial to back it up, Exparel has been given an assurance rating of 3 on our internal scale at Power."

Answered by AI

Are there any vacancies available for individuals to participate in this medical experiment?

"Per the information found on clinicaltrials.gov, this medical trial is still open to participants. Initially posted February 5th 2019 and last updated 2/13/2022."

Answered by AI

How many individuals are engaging in this investigation?

"Affirmative, according to information on clinicaltrials.gov, the medical research project is looking for participants at this time. The study was initially published on February 5th 2019 and last modified on 2/13/2022; 76 people are required from 1 facility."

Answered by AI

Are there any existing precedents of Exparel being utilized in a clinical context?

"Currently, there are 109 clinical trials underway examining the efficacy of Exparel. Of these studies, 18 have advanced to Phase 3 and are conducted in Philadelphia as well as 144 other sites across the nation."

Answered by AI

To what medical conditions is Exparel commonly applied?

"Exparel is a widely used medication for treating patients with pemphigus and other ailments like general anesthesia, acute nonspecific tenosynovitis, and lupus erythematous."

Answered by AI
~12 spots leftby Mar 2025